Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2016 2
2017 1
2019 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Development of small macrocyclic kinase inhibitors.
Ma J, Sanchez-Duffhues G, Caradec J, Benderitter P, Hoflack J, Dijke PT. Ma J, et al. Among authors: caradec j. Future Med Chem. 2022 Mar;14(6):389-391. doi: 10.4155/fmc-2021-0342. Epub 2022 Jan 14. Future Med Chem. 2022. PMID: 35029506 Free article. No abstract available.
Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer.
Nouri M, Massah S, Caradec J, Lubik AA, Li N, Truong S, Lee AR, Fazli L, Ramnarine VR, Lovnicki JM, Moore J, Wang M, Foo J, Gleave ME, Hollier BG, Nelson C, Collins C, Dong X, Buttyan R. Nouri M, et al. Among authors: caradec j. Clin Cancer Res. 2020 Apr 1;26(7):1678-1689. doi: 10.1158/1078-0432.CCR-19-0098. Epub 2020 Jan 9. Clin Cancer Res. 2020. PMID: 31919137
Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes.
Kharmate G, Hosseini-Beheshti E, Caradec J, Chin MY, Tomlinson Guns ES. Kharmate G, et al. Among authors: caradec j. PLoS One. 2016 May 6;11(5):e0154967. doi: 10.1371/journal.pone.0154967. eCollection 2016. PLoS One. 2016. PMID: 27152724 Free PMC article.
Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells.
Sánchez-Duffhues G, Williams E, Benderitter P, Orlova V, van Wijhe M, Garcia de Vinuesa A, Kerr G, Caradec J, Lodder K, de Boer HC, Goumans MJ, Eekhoff EMW, Morales-Piga A, Bachiller-Corral J, Koolwijk P, Bullock AN, Hoflack J, Ten Dijke P. Sánchez-Duffhues G, et al. Among authors: caradec j. JBMR Plus. 2019 Oct 7;3(11):e10230. doi: 10.1002/jbm4.10230. eCollection 2019 Nov. JBMR Plus. 2019. PMID: 31768489 Free PMC article.
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, Cox M, Collins C, Gleave M, Erho N, Alshalafa M, Davicioni E, Nelson C, Gregory-Evans S, Karnes RJ, Jenkins RB, Klein EA, Buttyan R. Nouri M, et al. Among authors: caradec j. Oncotarget. 2017 Mar 21;8(12):18949-18967. doi: 10.18632/oncotarget.14850. Oncotarget. 2017. PMID: 28145883 Free PMC article.